Attovia Therapeutics, Inc. (ATTO)
NASDAQ: ATTO · Real-Time Price · USD
19.86
+0.68 (3.55%)
At close: Aug 14, 2026, 4:00 PM EDT
19.56
-0.30 (-1.51%)
After-hours: Aug 14, 2026, 7:34 PM EDT

Attovia Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024
Period EndingMar '26 Dec '25 Dec '24
Revenue
1.351.35-
Revenue Growth
---
Gross Profit
-57.61-52.8-33.86
Operating Income
-71.01-67.16-41.55
Net Income
-64.13-60.63-39.8
Earnings Per Share
-15.89-15.35-11.27
EPS Growth
---

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024
Period EndingMar '26 Dec '25 Dec '24
Cash & Investments
132.62152.2769.32
Total Debt
4.85.26-
Net Cash (Debt)
127.82147.0169.32
Net Cash Growth
-112.06%-
Net Cash Per Share
31.6737.2219.63

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024
Period EndingMar '26 Dec '25 Dec '24
Operating Cash Flow
-63.21-59.2-35.04
Capital Expenditures
-0.81-2.31-1.77
Free Cash Flow
-64.02-61.51-36.81
Free Cash Flow Growth
---

Margins

Fiscal YearTTMFY 2025FY 2024
Period EndingMar '26 Dec '25 Dec '24
Operating Margin
-5260.00%-4974.74%-
Pretax Margin
-4750.52%-4490.89%-
Profit Margin
-4750.52%-4490.89%-
FCF Margin
-4742.07%-4556.44%-